Engrail Therapeutics has initiated the Phase II ENCALM clinical trial of ENX-102 for the treatment of patients with generalised anxiety disorder (GAD).
The multi-centre, placebo-controlled, randomised, double-blind study intends to assess the safety and efficacy of ENX-102 alone in GAD patients.
Go deeper with GlobalData
Male or female patients aged 18 to 65 years diagnosed with GAD are administered with a 2mg ENX-102 capsule for four weeks.
They are then followed for three weeks, including a tapered dose week and two weeks of a placebo in capsule form given once daily in the evening, for a nine-week total treatment period.
The placebo group is dosed once daily in the evening for six weeks out of a nine-week period.
Engrail Therapeutics chief scientific officer Kimberly Vanover said: “Translational and Phase I clinical data indicate central target engagement, with a highly differentiated safety and tolerability profile for ENX-102 against non-selective GABA-A positive allosteric modulators (PAMs) such as benzodiazepines.
“ENX-102 exhibits a long half-life and can be dosed once daily, without titration. These data support further evaluation of ENX-102 for efficacy in generalised anxiety disorder.”
ENX-102 is an investigational, subtype-selective, gamma-aminobutyric acid A (GABA-A) PAM that enhances the neurotransmission of GABA in α2, α3, and α5 receptors while blocking α1.
Engrail CEO and president Vikram Sudarsan said: “The initiation of Phase II and further advancement of the rest of our precision neuroscience pipeline makes 2023 a hallmark year for the organisation.”
The company is also engaged in developing transformational therapies that improve the lives of patients with neurodevelopmental, neuropsychiatric, and neurologic disorders.
